Logo image of BCAX

BICARA THERAPEUTICS INC (BCAX) Stock Overview

USA - NASDAQ:BCAX - US0554771032 - Common Stock

10.75 USD
+0.31 (+2.97%)
Last: 9/22/2025, 9:27:29 PM
10.75 USD
0 (0%)
After Hours: 9/22/2025, 9:27:29 PM

BCAX Key Statistics, Chart & Performance

Key Statistics
52 Week High28.09
52 Week Low7.8
Market Cap586.52M
Shares54.56M
Float43.93M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-3.17
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO09-13 2024-09-13
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


BCAX short term performance overview.The bars show the price performance of BCAX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20

BCAX long term performance overview.The bars show the price performance of BCAX in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of BCAX is 10.75 USD. In the past month the price decreased by -9.21%. In the past year, price decreased by -57.74%.

BICARA THERAPEUTICS INC / BCAX Daily stock chart

BCAX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.02 393.22B
AMGN AMGEN INC 13.11 153.97B
GILD GILEAD SCIENCES INC 14.53 139.58B
VRTX VERTEX PHARMACEUTICALS INC 22.62 98.23B
REGN REGENERON PHARMACEUTICALS 13.05 63.14B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 60.16B
ARGX ARGENX SE - ADR 79.83 45.29B
ONC BEONE MEDICINES LTD-ADR 5.9 40.16B
INSM INSMED INC N/A 30.65B
NTRA NATERA INC N/A 24.59B
BNTX BIONTECH SE-ADR N/A 23.73B
BIIB BIOGEN INC 8.79 20.62B

About BCAX

Company Profile

BCAX logo image Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company is headquartered in Boston, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2024-09-13. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.

Company Info

BICARA THERAPEUTICS INC

116 Huntington Avenue, Suite 703

Boston MASSACHUSETTS US

Employees: 55

BCAX Company Website

Phone: 16174684219

BICARA THERAPEUTICS INC / BCAX FAQ

What is the stock price of BICARA THERAPEUTICS INC today?

The current stock price of BCAX is 10.75 USD. The price increased by 2.97% in the last trading session.


What is the ticker symbol for BICARA THERAPEUTICS INC stock?

The exchange symbol of BICARA THERAPEUTICS INC is BCAX and it is listed on the Nasdaq exchange.


On which exchange is BCAX stock listed?

BCAX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for BICARA THERAPEUTICS INC stock?

14 analysts have analysed BCAX and the average price target is 32.06 USD. This implies a price increase of 198.21% is expected in the next year compared to the current price of 10.75. Check the BICARA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BICARA THERAPEUTICS INC worth?

BICARA THERAPEUTICS INC (BCAX) has a market capitalization of 586.52M USD. This makes BCAX a Small Cap stock.


How many employees does BICARA THERAPEUTICS INC have?

BICARA THERAPEUTICS INC (BCAX) currently has 55 employees.


What are the support and resistance levels for BICARA THERAPEUTICS INC (BCAX) stock?

BICARA THERAPEUTICS INC (BCAX) has a support level at 10.43 and a resistance level at 11.35. Check the full technical report for a detailed analysis of BCAX support and resistance levels.


Should I buy BICARA THERAPEUTICS INC (BCAX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BICARA THERAPEUTICS INC (BCAX) stock pay dividends?

BCAX does not pay a dividend.


What is the Price/Earnings (PE) ratio of BICARA THERAPEUTICS INC (BCAX)?

BICARA THERAPEUTICS INC (BCAX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.17).


What is the Short Interest ratio of BICARA THERAPEUTICS INC (BCAX) stock?

The outstanding short interest for BICARA THERAPEUTICS INC (BCAX) is 12.27% of its float. Check the ownership tab for more information on the BCAX short interest.


BCAX Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to BCAX. When comparing the yearly performance of all stocks, BCAX is a bad performer in the overall market: 88.7% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BCAX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to BCAX. BCAX has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BCAX Financial Highlights

Over the last trailing twelve months BCAX reported a non-GAAP Earnings per Share(EPS) of -3.17. The EPS decreased by -302.87% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -22.64%
ROE -23.59%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%12.05%
Sales Q2Q%N/A
EPS 1Y (TTM)-302.87%
Revenue 1Y (TTM)N/A

BCAX Forecast & Estimates

14 analysts have analysed BCAX and the average price target is 32.06 USD. This implies a price increase of 198.21% is expected in the next year compared to the current price of 10.75.


Analysts
Analysts82.86
Price Target32.06 (198.23%)
EPS Next Y11.85%
Revenue Next YearN/A

BCAX Ownership

Ownership
Inst Owners82.23%
Ins Owners1.46%
Short Float %12.27%
Short Ratio17.92